HIMS went into Monday’s close already under pressure. It came out worse.
Hims & Hers Health closed the regular session down 11.77%, then reported Q3 revenue of $890.4 million after the bell. The stock fell an additional 3% in after-hours trading after the company swung to a GAAP net loss and lowered forward guidance. The telehealth platform posted a Q3 GAAP loss of $0.14 per diluted share, versus GAAP earnings of $0.06 a year earlier, on revenue of $890.4 million.
Market Snapshot
The after-hours drop came after the telehealth provider reported a surprise third-quarter net loss, driven by a shift toward branded drugs in place of compounded ones and reduced full-year adjusted core profit guidance. HIMS stock has dropped about 29% year to date. The 52-week high is $42.70. At roughly $22, the stock is sitting about 48% below that peak.
Stocks in Focus
HIMS: Revenue of approximately $890 million grew 49% year over year, subscribers reached nearly 2.8 million, up 13%, full-year revenue guidance was tightened to $3.13 billion to $3.15 billion, and adjusted EBITDA guidance was reduced to $257 million to $277 million.
The subscriber number requires a closer read. The 2.788 million subscriber count was down by about 100,000 from the prior quarter. Management attributed this to deliberately lower marketing spend in U.S. weight loss and a brand transition overseas.
Margin is the pressure point. Gross margin fell sharply to 57% from 74% a year earlier as Hims shifted toward costlier branded weight-loss drugs and expanded internationally. Q4 revenue guidance came in at $885 million at the midpoint, well below analyst consensus of $953.1 million, and full-year adjusted EBITDA guidance of $267 million at the midpoint fell short of the $294.3 million consensus.
The Eli Lilly partnership, announced just days before earnings, adds complexity to the margin picture. Branded medications generally produce lower margins than compounded alternatives, meaning higher patient volumes may not translate into comparable profit growth. The platform already sells Wegovy and Ozempic from Novo Nordisk, so Hims now carries GLP-1 drugs from both leading obesity-drug makers. More revenue, thinner economics.
What Traders Should Watch
- Open price action: With roughly 15% of combined losses already in the market, watch for whether sellers continue to press or whether dip-buyers step in. Volume Monday was 48.7 million shares against an average of 10.9 million.
- Gross margin trajectory: Gross margin was 57% in Q3 2026, down from 74% in Q3 2025. Any guidance commentary on stabilization matters.
- NVO and LLY read-through: The continued pivot to branded drugs benefits both Novo Nordisk and Eli Lilly by routing telehealth volume through their products at self-pay prices. Hims absorbing the margin pain is part of that tradeoff.
Risk Radar
Management flagged that deferred revenue from accelerating membership in weight-loss categories will negatively impact revenue and adjusted EBITDA by at least $20 million for the full year, as certain December membership payments will not be recognized until January. That is a structural accounting drag, not a one-off.
Wall Street expects a return to GAAP profitability over the next 12 months, with analysts forecasting full-year EPS turning positive. That path now looks narrower after the EBITDA guidance cut. Whether the market gives management the benefit of the doubt hinges on Q4 execution and what the Lilly ramp actually delivers on margins.
The Cheat Sheet
- Top Theme: HIMS is growing revenue fast and losing profitability faster. The branded GLP-1 pivot is working commercially; the economics are still being figured out.
- Stock to Watch: HIMS at the open, entering Tuesday down nearly 15% combined. Watch the $22 level as near-term support.
- Biggest Risk: The Q4 revenue guide of $875 million to $895 million is 7% below consensus. If the market re-rates HIMS on a lower growth multiple, the sell-off has further to go.
- One Thing to Remember: Subscriber count fell quarter over quarter even as revenue per subscriber climbed about 30%. That is a mix shift, not a growth problem yet, but it is worth watching every quarter from here.
